EMA Authorised: Sprycel (dasatinib) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA authorised Sprycel (dasatinib). It covers chronic myeloid leukemia (BCR-ABL positive) and precursor cell lymphoblastic leukemia-lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Status: Authorised. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 24/02/2026